FORT WORTH, Texas, Oct. 16 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM) a rapidly growing provider of specialty medical products, announced today that its subsidiary Wound Care Innovations, LLC will exhibit at the 24th Annual Clinical Symposium on Advances in Skin & Wound Care: The Conference for Prevention and Healing, which opens on October 22 in San Antonio.
Dr. Jane Fore MD, FAPWCA, FACCWS, medical director of the Tri-State Wound Care and Hyperbaric Center in Clarkston, WA, will present the results of her clinical study that showed that the use of hydrolyzed collagen (CellerateRx) increased the efficiency of healing in skin tears/flaps. Most were resolved within one week with a single application. Her abstract is entitled, “Activated Collagen: An Evidence Based Skin Tear Study.”
Over 1100 multidisciplinary practitioners—nurses, physicians, podiatrists, physical therapists, dieticians, and others who manage skin and wound care patients across the continuum of health care are expected to attend. The conference will provide continuing-education needs of multidisciplinary skin and wound care practitioners, from novice to expert, with educational sessions and interactive workshops that offer comprehensive wound management strategies.
Dr. Fore said, “I am delighted to be presenting this abstract on the use of CellerateRx on skin tears and flaps. I have been using CellerateRx in my wound care protocols for over five years. It is an essential part of my successful wound care treatments. More of the regional nursing homes in my area are taking my skin tear protocol (CellerateRx) and are adapting it into their facilities due to the outcomes and cost effectiveness.”
Cathy Bradshaw, president of Wound Care Innovations, said, “Skin tears represent a major problem in the elderly and compromised patients. Untreated skin tears can serve as a portal of entry for infection and be a source of pain for the patient. Their treatment can also have an impact on facilities’ resources. This evidence based abstract demonstrates that the use of CellerateRx is not only effective in the management of skin tears, but also very cost effective as well, as shown by resolution with only one application.”
CellerateRx is FDA cleared for use on acute and chronic wounds which includes but is not limited to pressure ulcers (stages I-IV), traumatic wounds, diabetic ulcers, surgical wounds, venous stasis ulcers, ulcers due to arterial insufficiency, superficial wounds, and first and second degree burns.
For more information about Wound Care Innovations go to www.celleraterx.com
About Wound Management Technologies, Inc.:
Wound Management Technologies, through its subsidiary Wound Care Innovations, markets and distributes wound care products to the healthcare market under patented technology licensed to the company. The company is positioned and seeks to be a leading provider of wound care products. The company’s corporate headquarters are in Fort Worth, Texas. For more information please visit the company's website at www.celleraterx.com.
An online investor kit including press releases, current price quotes, stock charts and other valuable information for investors may be found at www.hawkassociates.com.
A profile for investors can be accessed at http://www.hawkassociates.com/clients/profile/wnmd.cfm.
To receive free e-mail notification of future releases for Wound Management Technologies, sign up at www.hawkassociates.com/about/alert/.
Safe Harbor Statement Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
SOURCE Wound Management Technologies, Inc.
Advertisement
Dr. Jane Fore MD, FAPWCA, FACCWS, medical director of the Tri-State Wound Care and Hyperbaric Center in Clarkston, WA, will present the results of her clinical study that showed that the use of hydrolyzed collagen (CellerateRx) increased the efficiency of healing in skin tears/flaps. Most were resolved within one week with a single application. Her abstract is entitled, “Activated Collagen: An Evidence Based Skin Tear Study.”
Advertisement
Over 1100 multidisciplinary practitioners—nurses, physicians, podiatrists, physical therapists, dieticians, and others who manage skin and wound care patients across the continuum of health care are expected to attend. The conference will provide continuing-education needs of multidisciplinary skin and wound care practitioners, from novice to expert, with educational sessions and interactive workshops that offer comprehensive wound management strategies.
Dr. Fore said, “I am delighted to be presenting this abstract on the use of CellerateRx on skin tears and flaps. I have been using CellerateRx in my wound care protocols for over five years. It is an essential part of my successful wound care treatments. More of the regional nursing homes in my area are taking my skin tear protocol (CellerateRx) and are adapting it into their facilities due to the outcomes and cost effectiveness.”
Cathy Bradshaw, president of Wound Care Innovations, said, “Skin tears represent a major problem in the elderly and compromised patients. Untreated skin tears can serve as a portal of entry for infection and be a source of pain for the patient. Their treatment can also have an impact on facilities’ resources. This evidence based abstract demonstrates that the use of CellerateRx is not only effective in the management of skin tears, but also very cost effective as well, as shown by resolution with only one application.”
CellerateRx is FDA cleared for use on acute and chronic wounds which includes but is not limited to pressure ulcers (stages I-IV), traumatic wounds, diabetic ulcers, surgical wounds, venous stasis ulcers, ulcers due to arterial insufficiency, superficial wounds, and first and second degree burns.
For more information about Wound Care Innovations go to www.celleraterx.com
About Wound Management Technologies, Inc.:
Wound Management Technologies, through its subsidiary Wound Care Innovations, markets and distributes wound care products to the healthcare market under patented technology licensed to the company. The company is positioned and seeks to be a leading provider of wound care products. The company’s corporate headquarters are in Fort Worth, Texas. For more information please visit the company's website at www.celleraterx.com.
An online investor kit including press releases, current price quotes, stock charts and other valuable information for investors may be found at www.hawkassociates.com.
A profile for investors can be accessed at http://www.hawkassociates.com/clients/profile/wnmd.cfm.
To receive free e-mail notification of future releases for Wound Management Technologies, sign up at www.hawkassociates.com/about/alert/.
Safe Harbor Statement Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
SOURCE Wound Management Technologies, Inc.
